Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus CEFTAZIDIME SODIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus CEFTAZIDIME SODIUM IN PLASTIC CONTAINER.
CEFIZOX vs CEFTAZIDIME SODIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic